E
Emil L. Fosbøl
Researcher at Copenhagen University Hospital
Publications - 286
Citations - 8091
Emil L. Fosbøl is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 40, co-authored 204 publications receiving 6168 citations.
Papers
More filters
Journal ArticleDOI
Association of National Initiatives to Improve Cardiac Arrest Management With Rates of Bystander Intervention and Patient Survival After Out-of-Hospital Cardiac Arrest
Mads Wissenberg,Freddy Lippert,Fredrik Folke,Peter Weeke,Carolina Malta Hansen,Erika Frischknecht Christensen,Henning Jans,Poul Anders Hansen,Torsten Lang-Jensen,Jonas Bjerring Olesen,Jesper Lindhardsen,Emil L. Fosbøl,Søren Loumann Nielsen,Gunnar Gislason,Lars Køber,Christian Torp-Pedersen +15 more
TL;DR: An increase in survival following out-of-hospital cardiac arrest was significantly associated with a concomitant increase in bystander CPR in Denmark between 2001 and 2010, and the number of survivors per 100,000 persons increased significantly.
Journal ArticleDOI
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Tina Ken Schramm,Gunnar Gislason,Allan Vaag,Jeppe Nørgaard Rasmussen,Fredrik Folke,Morten Lock Hansen,Emil L. Fosbøl,Lars Køber,Mette Lykke Norgaard,Mette Madsen,Peter Riis Hansen,Christian Torp-Pedersen +11 more
TL;DR: Monotherapy with the most used ISs, including glimepiride, glibenclamide, glipizide, and tolbutamide, seems to be associated with increased mortality and cardiovascular risk compared with metformin, and gliclazide and repaglinide appear to beassociated with a lower risk than other ISs.
Journal ArticleDOI
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Emil L. Fosbøl,Jawad H. Butt,Lauge Østergaard,Charlotte Andersson,Christian Selmer,Kristian Kragholm,Morten Schou,Matthew Phelps,Gunnar Gislason,Gunnar Gislason,Thomas A. Gerds,Christian Torp-Pedersen,Lars Køber +12 more
TL;DR: Findings do not support discontinuation of ACEI/ARB medications that are clinically indicated in the context of the COVID-19 pandemic, and prior use ofACEI/ARBs was not significantly associated with CO VID-19 diagnosis among patients with hypertension or with mortality or severe disease among patients diagnosed as having COIDs.
Journal ArticleDOI
Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study
Anne-Marie Schjerning Olsen,Emil L. Fosbøl,Jesper Lindhardsen,Fredrik Folke,Mette Charlot,Christian Selmer,Morten Lamberts,Jonas Bjerring Olesen,Lars Køber,Peter Riis Hansen,Christian Torp-Pedersen,Gunnar Gislason +11 more
TL;DR: In this paper, the duration of nonsteroidal anti-inflammatory drugs (NSAIDs) treatment and cardiovascular risk in a nationwide cohort of patients with prior myocardial infarction (MI) was studied.
Journal ArticleDOI
Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.
Gunnar Gislason,Jeppe Nørgaard Rasmussen,Steen Z. Abildstrom,Tina Ken Schramm,Morten Lock Hansen,Emil L. Fosbøl,Rikke Sørensen,Fredrik Folke,Pernille Buch,Niels Gadsbøll,Søren K. Rasmussen,Henrik E. Poulsen,Lars Køber,Mette Madsen,Christian Torp-Pedersen +14 more
TL;DR: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity, inasmuch as even commonly used NSAIDs exerted increased risk.